MRI Can Pinpoint Invasive Lobular Breast Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 9
Volume 8
Issue 9

NEW ORLEANS-Magnetic resonance imaging (MRI) of the breast is more accurate than conventional methods for identifying the extent of invasive lobular carcinoma, according to a study presented at the American Roentgen Ray Society annual meeting.

NEW ORLEANS—Magnetic resonance imaging (MRI) of the breast is more accurate than conventional methods for identifying the extent of invasive lobular carcinoma, according to a study presented at the American Roentgen Ray Society annual meeting.

Lobular carcinoma is difficult to detect by mammography because the tumor cells form a linear array that does not cause architectural distortion, said Rose E. Heller, MD, a fellow in the Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia.

“This form of cancer may be hidden within the normal breast tissue on the mammogram and therefore cannot be easily seen,” Dr. Heller said. These tumors account for about 10% of breast cancers and are often multifocal in nature. Residual disease is more frequently a problem with lobular carcinoma than with infiltrating ductal carcinoma.

Dr. Heller and her colleagues studied 31 women with lobular carcinoma, 32 to 69 years old, who were enrolled in various protocols at their institution: 10 were studied following excisional biopsy, 9 had a positive screening mammogram, 8 had palpable abnormalities, 1 had a positive axillary lymph node, and 3 were excluded due to lack of clinical follow-up. Contrast-enhanced MR images were compared with mammography and ultrasound results, and correlated with pathologic findings after excision or mastectomy.

Tumor extent on MR imaging correlated with pathologic tumor extent in 89% of the cases, Dr. Heller said. In two cases, MR imaging overestimated disease extent, and, in one instance, disease extent was underestimated.

MR imaging alone accurately detected tumor extent in 20 of the 28 cases (71%), whereas in only one case was tumor extent determined accurately by mammography alone. Both MRI and mammography identified tumor extent in 5 cases.

Only 12 women had ultrasound studies performed, but in 8 cases, ultrasound underestimated tumor extent. In 4 cases, both MR imaging and ultrasound were able to accurately assess tumor extent.

Clinically, MR imaging upstaged 20 of the 28 patients. While 6 women went directly to mastectomy, 13 opted for wider excision, with 8 of them ultimately undergoing mastectomy. For 4 patients, MR imaging would have predicted the need for mastectomy initially. Thus, this procedure could be used to guide surgical planning.

Both Dr. Heller and one of her collaborators, Susan Orel, MD, commented that MR imaging could be used to plan the fastest and most accurate treatments for women with lobular breast cancer. “Although our work needs to be expanded, the results are compelling for this small group,” Dr. Heller said.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Related Content